title: A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection.
abstract: Post-transplant protocols for hepatitis B (HBV) prophylaxis using high-dose intravenous hepatitis B immune globulin (10,000 IU) with or without lamivudine are commonly reported. Our centre has previously reported a low-dose intramuscular (i.m.) protocol and lamivudine with excellent results. There have been, however, no pharmacokinetic studies of i.m. hepatitis B immune globulin (HBIG) in this setting. The objective of this study was to determine the pharmacokinetic profile of i.m. HBIG in long-term post-liver-transplant recipients to determine a rational dosing protocol. Six stable liver transplant recipients receiving monthly i.m. HBIG injections for greater than one year were enrolled in this study. All patients had no detectable HBV DNA levels. HBIG titers (anti-HBs) were measured predose, then three times weekly for four weeks and then twice weekly until the serum HBIG titers were 100 IU/L or less. The pharmacokinetic parameters were calculated using noncompartment methods. The mean time to maximum concentration was 10.5 d (range 4-20 d) and the mean half-life was 20 d (range 13.5-23.5 d). Based on these pharmacokinetic parameters in stable long-term post-transplant patients, a rational dosing protocol was developed that allows for more appropriate utility of HBIG and improved patient convenience.
authors.affiliation: Vancouver Hospital and Health Sciences Centre, and Faculty of Pharmaceutical Sciences, University of British Columbia and the British Columbia Transplant Society, Canada.
authors.forename: N
authors.initials: N
authors.lastname: Partovi
authors.forename: M W
authors.initials: MW
authors.lastname: Guy
authors.forename: M H
authors.initials: MH
authors.lastname: Ensom
authors.forename: M A
authors.initials: MA
authors.lastname: Noble
authors.forename: E M
authors.initials: EM
authors.lastname: Yoshida
mesh_terms: D019540:Area Under Curve; D004279:DNA, Viral / Q000097:blood; D006207:Half-Life; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000378:metabolism* / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D004279:DNA, Viral; D007136:Immunoglobulins; C045213:hepatitis B hyperimmune globulin